Table of Contents 
ISRN Urology
Volume 2014, Article ID 717295, 4 pages
http://dx.doi.org/10.1155/2014/717295
Review Article

Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy

Muhammad Z. Aslam and P. N. Matthews

Department of Urology, University Hospital of Wales, Cardiff CF14 4XW, UK

Received 5 November 2013; Accepted 10 December 2013; Published 23 January 2014

Academic Editors: R. Autorino and J. H. Ku

Copyright © 2014 Muhammad Z. Aslam and P. N. Matthews. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Cancer Research UK, UK kidney statistics, 2008, http://info.cancerresearchuk.org/cancerstats/types/kidney.
  2. M. Murai and M. Oya, “Renal cell carcinoma: etiology, incidence and epidemiology,” Current Opinion in Urology, vol. 14, no. 4, pp. 229–233, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. S. Lam, O. Shvarts, J. T. Leppert, R. A. Figlin, and A. S. Belldegrun, “Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy,” Journal of Urology, vol. 173, no. 6, pp. 1853–1862, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara, “Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma,” Journal of Clinical Oncology, vol. 17, no. 8, pp. 2530–2540, 1999. View at Google Scholar · View at Scopus
  5. G. Fyfe, R. I. Fisher, S. A. Rosenberg, M. Sznol, D. R. Parkinson, and A. C. Louie, “Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy,” Journal of Clinical Oncology, vol. 13, no. 3, pp. 688–696, 1995. View at Google Scholar · View at Scopus
  6. E. Jonasch and F. G. Haluska, “Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities,” Oncologist, vol. 6, no. 1, pp. 34–55, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. R. J. Motzer, T. E. Hutson, P. Tomczak et al., “Sunitinib versus interferon alfa in metastatic renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 2, pp. 115–124, 2007. View at Publisher · View at Google Scholar
  8. M. M. Walther, R. B. Alexander, G. H. Weiss et al., “Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma,” Urology, vol. 42, no. 3, pp. 250–258, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. R. C. Flanigan, S. E. Salmon, B. A. Blumenstein et al., “Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer,” New England Journal of Medicine, vol. 345, no. 23, pp. 1655–1659, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. G. H. J. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester, “Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial,” Lancet, vol. 358, no. 9286, pp. 966–970, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. J. E. Montie, B. H. Stewart, R. A. Starffon et al., “The role of adjuvant nephrectomy in patients with mRCC,” Journal of Urology, vol. 117, pp. 272–275, 1977. View at Google Scholar
  12. B. I. Rini, S. C. Campbell, and B. Escudier, “Renal cell carcinoma,” The Lancet, vol. 373, no. 9669, pp. 1119–1132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. R. Franklin, R. Figlin, J. Rauch, B. Gitlitz, and A. Belldegrun, “Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience,” Seminars in Urologic Oncology, vol. 14, no. 4, pp. 230–236, 1996. View at Google Scholar · View at Scopus
  14. R. T. Bennett, S. E. Lerner, H. C. Taub, J. P. Dutcher, and J. Fleischmann, “Cytoreductive surgery for stage IV renal cell carcinoma,” Journal of Urology, vol. 154, no. 1, pp. 32–34, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. M. L. Fallick, D. F. McDermott, D. Larock, J. P. Long, and M. B. Atkins, “Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma,” Journal of Urology, vol. 158, no. 5, pp. 1691–1695, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. S. H. Culp, N. M. Tannir, E. J. Abel et al., “Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?” Cancer, vol. 116, no. 14, pp. 3378–3388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. D. G. Skinner, R. B. Colvin, C. D. Vermillion, R. C. Pfister, and W. F. Leadbetter, “Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases,” Cancer, vol. 28, no. 5, pp. 1165–1177, 1971. View at Google Scholar · View at Scopus
  18. W. Kassouf, R. Sanchez-Ortiz, P. Tamboli et al., “Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson cancer center experience,” Urology, vol. 69, no. 5, pp. 835–838, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. Surveillance, Epidemiology and End Results (SEER), National Cancer institute, United Stataes National Institute of Health, 2005, http://seer.cancer.gov/.
  20. A. K. Kader, P. Tamboli, T. Luongo et al., “Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson cancer center experience,” Journal of Urology, vol. 177, no. 3, pp. 855–861, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. K. R. Han, A. J. Pantuck, M. H. T. Bui et al., “Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma,” Urology, vol. 61, no. 2, pp. 314–319, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Latif, K. Tory, J. Gnarra et al., “Identification of the von Hippel-Lindau disease tumor suppressor gene,” Science, vol. 260, no. 5112, pp. 1317–1320, 1993. View at Google Scholar · View at Scopus
  23. D. S. Krause and R. A. van Etten, “Tyrosine kinases as targets for cancer therapy,” The New England Journal of Medicine, vol. 353, no. 2, pp. 172–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. J. Motzer, T. E. Hutson, P. Tomczak et al., “Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 22, pp. 3584–3590, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. T. K. Choueiri, W. Xie, C. Kollmannsberger et al., “The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy,” Journal of Urology, vol. 185, no. 1, pp. 60–66, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Warren, P. M. Venner, S. North et al., “A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment,” Journal of the Canadian Urological Association, vol. 3, no. 4, pp. 281–289, 2009. View at Google Scholar · View at Scopus
  27. “Clinical trial to assess the importance of nephrectomy (CARMENA),” US National Institutes of Health, http://clinicaltrials.gov/ct2/show/NCT00930033.
  28. A. Bex, E. Jonasch, Z. Kirkali et al., “Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials,” European Urology, vol. 58, no. 6, pp. 819–828, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Jonasch, C. G. Wood, S. F. Matin et al., “Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 25, pp. 4076–4081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. “Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer,” US National Institutes of Health Web, http://Clinicaltrials.gov/ct2/show/NCT01099423.